{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:14:31Z","timestamp":1790957671701,"version":"4.1.0"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T00:00:00Z","timestamp":1697500800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"The National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82174204"],"award-info":[{"award-number":["82174204"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Ivabradine improves cardiac function in patients with heart failure, but its effect on dilated cardiomyopathy (DCM) remains unclear. We performed a systematic review and meta-analysis to study the efficacy and potential mechanisms of ivabradine's effect on cardiac function and prognosis in patients with DCM.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We searched PubMed, Cochrane Library, Embase, Web of Science, and four registers through September 28, 2022. All controlled trials of ivabradine for the treatment of DCM with congestive heart failure were included. Articles were limited to English, with the full text and necessary data available. We performed random- or fixed effects meta-analyses for all included outcome measures and compared the effect sizes for outcomes in patients treated with and without ivabradine. The quality of the studies was assessed using the Cochrane risk-of-bias tool for randomized trials (RoB2.0).<\/jats:p><\/jats:sec><jats:sec><jats:title>Findings<\/jats:title><jats:p>Five trials with 357 participants were included. The pooled risk ratio was 0.48 [95% confidence interval (CI) (0.18, 1.25)] for all-cause mortality and 0.38 [95% CI (0.12, 1.23)] for cardiac mortality. The pooled mean difference was \u221215.95 [95% CI (\u221219.97, \u221211.92)] for resting heart rate, 3.96 [95% CI (0.99, 6.93)] for systolic blood pressure, 2.93 [95% CI (2.09, 3.77)] for left ventricular ejection fraction, \u22125.90 [95% CI (\u22129.36, \u22122.44)] for left ventricular end-systolic diameter, \u22123.41 [95% CI (\u22125.24, \u22121.58)] for left ventricular end-diastolic diameter, \u22120.81 [95% CI (\u22121.00, \u22120.62)] for left ventricular end-systolic volume, \u22120.67 [95% CI (\u22120.86, \u22120.48)] for left ventricular end-diastolic volume, \u221211.01 [95% CI (\u221219.66, \u22122.35)] for Minnesota Living with Heart Failure score, and \u22120.52 [95% CI (\u22120.73, \u22120.31)] for New York Heart Association class.<\/jats:p><\/jats:sec><jats:sec><jats:title>Interpretation<\/jats:title><jats:p>Ivabradine reduces heart rate and ventricular volume, and improves cardiac function in patients with DCM, but showed no significant effect on the prognosis of patients.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcvm.2023.1149351","type":"journal-article","created":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T06:27:26Z","timestamp":1697524046000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["The effect of ivabradine therapy on dilated cardiomyopathy patients with congestive heart failure: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"10","author":[{"given":"Juntao","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiedong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingjie","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haifei","family":"Lou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanxuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hangyuan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jufang","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,10,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/s41572-019-0084-1","article-title":"Dilated cardiomyopathy","volume":"5","author":"Schultheiss","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"B2","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1111\/joim.12944","article-title":"Dilated cardiomyopathy: from epidemiologic to genetic phenotypes a translational review of current literature","volume":"286","author":"Reichart","year":"2019","journal-title":"J Intern Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"2996","DOI":"10.1016\/j.jacc.2016.03.590","article-title":"The diagnosis and evaluation of dilated cardiomyopathy","volume":"67","author":"Japp","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/nrcardio.2013.105","article-title":"Dilated cardiomyopathy: the complexity of a diverse genetic architecture","volume":"10","author":"Hershberger","year":"2013","journal-title":"Nat Rev Cardiol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1161\/circulationaha.116.027134","article-title":"Personalizing risk stratification for sudden death in dilated cardiomyopathy the past, present, and future","volume":"136","author":"Halliday","year":"2017","journal-title":"Circulation"},{"key":"B6","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/s0140-6736(16)31713-5","article-title":"Dilated Cardiomyopathy","volume":"390","author":"Weintraub","year":"2017","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2801","DOI":"10.3390\/ijms24032801","article-title":"Therapeutic use and molecular aspects of ivabradine in cardiac remodeling: a review","volume":"24","author":"Kamisah","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B8","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1016\/s0140-6736(10)61259-7","article-title":"Heart rate as a risk factor in chronic heart failure (shift): the association between heart rate and outcomes in a randomised placebo-controlled trial","volume":"376","author":"Boehm","year":"2010","journal-title":"Lancet"},{"key":"B9","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1002\/phar.2391","article-title":"Beyond heart failure and ischemic heart disease: a scoping review of novel uses of ivabradine in adults","volume":"40","author":"Hellenbart","year":"2020","journal-title":"Pharmacotherapy"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1016\/j.jacc.2017.07.725","article-title":"Ivabradine in children with dilated cardiomyopathy and symptomatic chronic heart failure","volume":"70","author":"Bonnet","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1016\/j.jacc.2017.08.038","article-title":"The clinical use of ivabradine","volume":"70","author":"Koruth","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1161\/circulationaha.115.018094","article-title":"Ivabradine: role in the chronic heart failure armamentarium","volume":"133","author":"Psotka","year":"2016","journal-title":"Circulation"},{"key":"B13","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The prisma 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Br Med J"},{"key":"B14","doi-asserted-by":"publisher","first-page":"n160","DOI":"10.1136\/bmj.n160","article-title":"Prisma 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Br Med J"},{"key":"B15","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13643-020-01542-z","article-title":"Prisma-S: an extension to the prisma statement for reporting literature searches in systematic reviews","volume":"10","author":"Rethlefsen","year":"2021","journal-title":"Syst Rev"},{"key":"B16","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"Rob 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"B17","first-page":"736","volume-title":"Cochrane handbook for systematic reviews of interventions version 6.4","author":"Higgins","year":"2023"},{"key":"B18","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.ehj.2011.09.001","article-title":"Efficacy of ivabradine in idiopathic dilated cardiomyopathy patients with chronic heart failure","volume":"63","author":"Mansour","year":"2011","journal-title":"Egypt Heart J"},{"key":"B19","doi-asserted-by":"publisher","first-page":"227","DOI":"10.5603\/CJ.a2014.0057","article-title":"I(F) current inhibitor ivabradine in patients with idiopathic dilated cardiomyopathy: impact on the exercise tolerance and quality of life","volume":"22","author":"Abdel-Salam","year":"2015","journal-title":"Cardiol J"},{"key":"B20","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.ihj.2017.08.009","article-title":"Heart rate manipulation in dilated cardiomyopathy: assessing the role of ivabradine","volume":"70","author":"Raja","year":"2018","journal-title":"Indian Heart J"},{"key":"B21","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ijcard.2019.01.052","article-title":"Heart rate reduction strategy using ivabradine in end-stage duchenne cardiomyopathy","volume":"280","author":"Adorisio","year":"2019","journal-title":"Int J Cardiol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1002\/ejhf.876","article-title":"Effect of ivabradine in patients with heart failure with preserved ejection fraction: the edify randomised placebo-controlled trial","volume":"19","author":"Komajda","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1093\/eurheartj\/ehr343","article-title":"Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: results from the shift study","volume":"32","author":"Ekman","year":"2011","journal-title":"Eur Heart J"},{"key":"B24","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/s0140-6736(10)61198-1","article-title":"Ivabradine and outcomes in chronic heart failure (shift): a randomised placebo-controlled study","volume":"376","author":"Swedberg","year":"2010","journal-title":"Lancet"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.2174\/1568026619666190809093144","article-title":"Pharmacology of ivabradine and the effect on chronic heart failure","volume":"19","author":"Zhou","year":"2019","journal-title":"Curr Top Med Chem"},{"key":"B26","doi-asserted-by":"publisher","first-page":"784","DOI":"10.7326\/0003-4819-150-11-200906020-00006","article-title":"Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure","volume":"150","author":"McAlister","year":"2009","journal-title":"Ann Intern Med"},{"key":"B27","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s00392-012-0467-8","article-title":"Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the shift study","volume":"102","author":"Bohm","year":"2013","journal-title":"Clin Res Cardiol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.cardfail.2006.12.001","article-title":"Effect of chronic changes in heart rate on congestive heart failure","volume":"13","author":"Rao","year":"2007","journal-title":"J Card Fail"},{"key":"B29","doi-asserted-by":"publisher","first-page":"689","DOI":"10.2147\/dddt.S60591","article-title":"Ivabradine, coronary artery disease, and heart failure: beyond rhythm control","volume":"8","author":"Scicchitano","year":"2014","journal-title":"Drug Des Dev Ther"},{"key":"B30","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1253\/circj.CJ-10-0925","article-title":"Heart rate and heart failure not a simple relationship","volume":"75","author":"Heusch","year":"2011","journal-title":"Circ J"},{"key":"B31","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1097\/hco.0000000000000266","article-title":"Heart rate and heart failure","volume":"31","author":"Yip","year":"2016","journal-title":"Curr Opin Cardiol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1155\/2021\/1257283","article-title":"Ivabradine ameliorates cardiac function in heart failure with preserved and reduced ejection fraction via upregulation of mir-133a","volume":"2021","author":"Shao","year":"2021","journal-title":"Oxidative Med Cell Longev"},{"key":"B33","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1155\/2016\/949320","article-title":"Impact of ivabradine on inflammatory markers in chronic heart failure","volume":"2016","author":"Rohm","year":"2016","journal-title":"J Immunol Res"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1002\/jcp.27070","article-title":"Inhibition of jnk and P38 mapk-mediated inflammation and apoptosis by ivabradine improves cardiac function in streptozotocin-induced diabetic cardiomyopathy","volume":"234","author":"Zuo","year":"2019","journal-title":"J Cell Physiol"},{"key":"B35","first-page":"953","article-title":"Dilated cardiomyopathy","volume-title":"Practice of internal medicine","author":"Chen","year":"2022"},{"key":"B36","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1177\/2040622318784556","article-title":"The therapeutic role of ivabradine in heart failure","volume":"9","author":"Badu-Boateng","year":"2018","journal-title":"Ther Adv Chronic Dis"},{"key":"B37","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1002\/jcp.24507","article-title":"Ivabradine protects against ventricular arrhythmias in acute myocardial infarction in the rat","volume":"229","author":"Mackiewicz","year":"2014","journal-title":"J Cell Physiol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1161\/jaha.113.000150","article-title":"Increased expression of hcn channels in the ventricular myocardium contributes to enhanced arrhythmicity in mouse failing hearts","volume":"2","author":"Kuwabara","year":"2013","journal-title":"J Am Heart Assoc"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1016\/j.hrthm.2021.03.020","article-title":"Effect of ivabradine on cardiac arrhythmias: antiarrhythmic or proarrhythmic?","volume":"18","author":"Marciszek","year":"2021","journal-title":"Heart Rhythm"},{"key":"B40","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3390\/jcm10204732","article-title":"Effect of ivabradine on cardiac ventricular arrhythmias: friend or foe?","volume":"10","author":"Okninska","year":"2021","journal-title":"J Clin Med"},{"key":"B41","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/s0140-6736(08)61170-8","article-title":"Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (beautiful): a randomised, double-blind, placebo-controlled trial","volume":"372","author":"Fox","year":"2008","journal-title":"Lancet"},{"key":"B42","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1002\/14651858.CD013004.pub2","article-title":"Ivabradine as adjuvant treatment for chronic heart failure","volume":"11","author":"Benstoem","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1007\/s11096-018-0715-8","article-title":"The effect of ivabradine therapy on heart failure patients with reduced ejection fraction: a systematic review and meta-analysis","volume":"40","author":"Hartmann","year":"2018","journal-title":"Int J Clin Phar"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/s0140-6736(10)62226-x","article-title":"Normal ranges of heart rate and respiratory rate in children from birth to 18 years of age: a systematic review of observational studies","volume":"377","author":"Fleming","year":"2011","journal-title":"Lancet"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1232404","DOI":"10.3389\/fcvm.2023.1232404","article-title":"Prognostic implications of left ventricular ejection fraction trajectory changes in heart failure","volume":"10","author":"Ding","year":"2023","journal-title":"Front Cardiovasc Med"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2023.1149351\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T06:27:30Z","timestamp":1697524050000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2023.1149351\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,17]]},"references-count":45,"alternative-id":["10.3389\/fcvm.2023.1149351"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2023.1149351","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,17]]},"article-number":"1149351"}}